42 Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody removab<SUP>?</SUP> (anti-CD3 X anti-EpCAM)

H.Sommer; B.Schmalfeldt; J.Pfisterer; M.Strohlein; M.R.Lichinitser; A.N.Makhson; R.Kimmig; A.Burges; P.Wimberger; V.A.Gorbounova

首页> 外文期刊>European Journal of Cancer Supplements >42 Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody removab^? (anti-CD3 X anti-EpCAM)

【24h】

42 Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody removab^? (anti-CD3 X anti-EpCAM)

机译：使用三功能双特异性抗体removab ^{？（抗CD3 X抗EpCAM）治疗卵巢癌伴有症状性腹水的I期研究42}

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2003年第5期|共页
作者
H.Sommer; B.Schmalfeldt; J.Pfisterer; M.Strohlein; M.R.Lichinitser; A.N.Makhson; R.Kimmig; A.Burges; P.Wimberger; V.A.Gorbounova;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients [J] . S.Loibl, J.Pfisterer, P.Wimberger, European Journal of Cancer Supplements . 2007,第4期

机译：5005 ORAL腹膜内注入三功能双特异性抗体catumaxomab（抗EpCAM×抗CD3）的随机，多中心，2剂量水平，开放标签IIa期研究，以选择难治性铂类上皮性卵巢癌患者的更好剂量水平
2. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). [J] . Jager M, Schoberth A, Ruf P, Cancer research: The official organ of the American Association for Cancer Research, Inc . 2012,第1期

机译：使用三功能抗体catumaxomab（抗EpCAM x抗CD3）治疗的恶性腹水患者的II / III期研究的免疫监测结果。
3. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study [J] . Martin Sebastian, Bernward Passlick, Hilke Friccius-Quecke, Cancer Immunology, Immunotherapy . 2007,第10期

机译：三功能单克隆抗体catumaxomab（抗EpCAM×抗CD3）治疗非小细胞肺癌患者：I期研究
4. Proteomic comparison of ascites from ovarian cancer patients and ovarian cancer cell lines using HPLC-orbitrap mass spectrometry [C] . Guangyu Zhang, Rodney Rocconi, Michael Finan, ASMS Conference on Mass Spectrometry and Allied Topics . 2008

机译：卵巢癌患者腹水和卵巢癌细胞系的蛋白质组学比较使用HPLC-横谱法质谱法
5. Psychological Distress during Ovarian Cancer Treatment: Improving Quality by Examining Patient Problems and Advanced Practice Nursing Interventions [D] . O'Sullivan, Cynthia Kline 2011

机译：卵巢癌治疗期间的心理困扰：通过检查患者问题和高级实践护理干预措施来提高质量
6. Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS) [O] . Lawrence G Lum, Minsig Choi, Archana Thakur, 2015

机译：五名晚期胰腺癌患者在抗CD3 x抗EGFR双特异性抗体武装的活化T细胞（BATS）的I期研究中
7. Tolerability and efficacy of the trifunctional antibody removab (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study [O] . 2004

机译：I / II期研究的结果：三功能抗体可瑞波（抗EpCAM x抗CD3）在卵巢癌引起的恶性腹水患者中的耐受性和疗效

42 Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody removab? (anti-CD3 X anti-EpCAM)

著录项

相似文献

相关主题

期刊订阅

42 Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody removab^? (anti-CD3 X anti-EpCAM)